To view this email as a web page, click here.

 
Dermatology Times
Surgery still best for basal cell carcinomas
There are many non-surgical treatments for basal cell carcinomas, but a physician say new treatments should be compared against surgery, which has the highest cure rate and lowest rate of recurrence.
ADVERTISEMENT
 
Dermatology Times
Treating moles and melanoma during pregnancy
A pregnancy-associated melanoma (PAM) prognosis does not appear to be worse than melanoma in non-pregnant controls, researchers report. Nonetheless, measures should be taken to protect the fetus in the treatment and imaging of PAM.
ADVERTISEMENT
 
Dermatology Times
The expanding role of dermatologists in immunotherapy
With immunotherapy as a key treatment for melanoma, dermatologists should be prepared to treat its cutaneous side effects and refer for adrenal sufficiency, uveitis, thyroid disease and other non-cutaneous side effects.
ADVERTISEMENT
 
Follow trends in biosimilars
Our partner site, Managed Healthcare Executive, has created a page solely devoted to issues surrounding biosimilars from new payment models to prescription trends. Learn more here.
 
ENGAGE WITH PEERS ON OUR NP & PA FORUM
 
Difficult-to-diagnose cases and the lessons learned
Four steps for NPs, PAs who want to take their careers beyond the clinic
The immune system, four immune-mediated skin diseases and why targeted therapies work
 
From our Latest Issue
 
Dermatology Times cover
Medical spa owners face increasing liability risks
 
Why FDA approval of cosmetics may be unnecessary
 
The need for entrepreneurship education in medical school and residency training
 
JOB OPPORTUNITIES
 
 
ADVERTISEMENT
Acne's effects are physical and emotional
Failure to treat acne early and effectively can lead to acne scarring. In this brief video, Dr. Joshua Zeichner discusses his approach to the treatment of acne for teens and young adults.
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.